Pamlab

Alfasigma USA, Inc. (formerly Pamlab) is an American medical food company, and a division of Alfasigma Group, of Bologna Italy.

Alfasigma's base of operations is located in Covington, Louisiana.

History

The company entered the pharmaceutical industry in 1957, initially introducing prescription cough/cold products. In 1987, Pamlab was purchased by Samuel and Judith Camp.[1]

In early 2013, Pamlab was purchased by Nestlé Health Science.[2]

In December 2016, Pamlab was purchased by Alfasigma Group of Bologna, Italy.[3]

Alfasigma USA, Inc. was sued by ExeGi Pharma LLC and the Italian inventor of probiotic VSL#3, Claudio De Simone, for making false advertising claims and ownership rights to VSL#3.[4][5][6]

According to court documents: "Defendant VSL Inc., and its licensees Alfasigma and Leadiant, having lost the right to sell the De Simone Formulation, decided to manufacture, market, and sell a different, inferior formulation (the “Fraudulent Formulation”) without conducting any tests to determine if the Fraudulent Formulation would be efficacious in any way".[6]  

A scientific article published in Frontiers in Immunology concluded: "These discrepancies may have a major impact on patient safety and on the liability of doctors when they prescribe a probiotic formulation made with different processes at different production sites from the formulation, which generated the original evidence, without properly informing the patients".[7]

A class action related to the VSL#3 scandal was recently opened in the USA.[8]

Products

Alfasigma USA, Inc. produces medical foods for people with diabetic peripheral neuropathy, early memory loss/Alzheimer's, high-risk pregnancy, depression, and other medical conditions.

Some of Pamlab's products include the following:

See also

References
  1. "Our History". Pamlab. Retrieved 2016-03-24.
  2. "Nestle buys U.S. medical foods firm Pamlab". Reuters. 26 February 2013. Retrieved 2016-03-24.
  3. "Alfasigma Expands Footprint" (PDF). 13 January 2017.
  4. Simone, C. De (2018). "Letter: what gastroenterologists should know about VSL#3". Alimentary Pharmacology & Therapeutics. 47 (5): 698–699. doi:10.1111/apt.14515. ISSN 1365-2036. PMID 29417631.
  5. "De Simone v. VSL Pharmaceuticals, Inc. et al, No. 8:2015cv01356 - Document 927 (D. Md. 2019)". Justia Law. Retrieved 2019-09-01.
  6. "Class Action" (PDF).
  7. Trinchieri, Vito; Laghi, Luca; Vitali, Beatrice; Parolin, Carola; Giusti, Ilaria; Capobianco, Daniela; Mastromarino, Paola; De Simone, Claudio (2017-11-06). "Efficacy and Safety of a Multistrain Probiotic Formulation Depends from Manufacturing". Frontiers in Immunology. 8: 1474. doi:10.3389/fimmu.2017.01474. ISSN 1664-3224. PMC 5681494. PMID 29163538.
  8. "Class Action Accuses Pharma Companies of Secretly Reformulating VSL#3 Probiotics Product". www.classaction.org. Retrieved 2019-09-01.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.